Antagonist G
| Code | Size | Price |
|---|
| TAR-T20481-25mg | 25mg | £837.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
Antagonist G is an anticancer peptide and is also a broad spectrum neuropeptide growth factor antagonist.
CAS:
115150-59-9
Formula:
C49H66N12O6S
Molecular Weight:
951.21
Purity:
0.98
SMILES:
CN[C@@H](Cc1ccccc1C(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O
References
1. MacKinnon AC, Waters C, Rahman I, Harani N, Rintoul R, Haslett C, Sethi T. [Arg(6), D-Trp(7,9), N(me)Phe(8)]-substance P (6-11) (antagonist G) induces AP-1 transcription and sensitizes cells to chemotherapy. Br J Cancer. 2000 Oct;83(7):941-8. PubMed PMID: 10970698; PubMed Central PMCID: PMC2374683.
2. Clive S, Webb DJ, MacLellan A, Young A, Byrne B, Robson L, Smyth JF, Jodrell DI. Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist. Clin Cancer Res. 2001 Oct;7(10):3071-8. PubMed PMID: 11595697.
3. Moreira JN, Gaspar R. Antagonist G-mediated targeting and cytotoxicity of liposomal doxorubicin in NCI-H82 variant small cell lung cancer. Braz J Med Biol Res. 2004 Aug;37(8):1185-92. Epub 2004 Jul 20. PubMed PMID: 15273819.
4. Jones DA, Cummings J, Langdon SP, Smyth JF. Preclinical studies on the broad-spectrum neuropeptide growth factor antagonist G. Gen Pharmacol. 1997 Feb;28(2):183-9. Review. PubMed PMID: 9013192.